Clinical trials: Mental Depression
Major Depressive Disorder
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
- Trial name
- NCT00775203
- Testing
- Trazodone Hydrochloride (HCl) Extended-Release Tablets
- Where
- 36 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Labopharm Inc.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder…
- Trial name
- VENTURA-7 (NCT06514742)
- Testing
- Aticaprant
- Where
- 84 sites in United States, Belgium and 7 more
- Volunteers
- 101 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder
Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder
The purpose of this study is to validate the effectiveness of using an integrated mobile sensing platform to deliver large-scale data-driven interventions to patients with depression.
- Trial name
- NCT02499094
- Testing
- Behavioral-data driven support
- Volunteers
- 1,004 people
- Sponsor
- Ginger.io
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Major Depressive Disorder
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and tolerability of ascending multiple oral doses of brexpiprazole as adjunctive therapy in the treatment of elderly subjects with MDD.
- Trial name
- NCT01670279
- Testing
- Brexpiprazole
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA2 (NCT06775379)
- Testing
- Azetukalner
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Major Depressive Disorder (MDD)
European Drug Utilization Study
The purpose of this retrospective observational study is to evaluate the characteristics of patients receiving Seroquel XR as treatment for their Major Depressive Disorder.
- Trial name
- EUDUS (NCT01594996)
- Where
- Germany
- Volunteers
- 814 people
- Sponsor
- AstraZeneca
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
To the best of the knowledge of the Principal Investigators, there was no randomised controlled trial to assess the potential cognitive improvement seen with Vortioxetine, in comparison with some other most commonly used SNRI…
- Trial name
- VENUS (NCT05104918)
- Testing
- Vortioxetine, Venlafaxine
- Volunteers
- 500 people
- Sponsor
- Scotmann Pharmaceuticals
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of treating participants with treatment-resistant depression (TRD) who have failed at least 2 (and no more than 6) prior antidepressant (AD) treatments in the current moderate…
- Trial name
- NCT03852160
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Sponsor
- Janssen-Cilag International NV
Major Depressive Disorder
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.
- Trial name
- NCT02272517
- Testing
- Vortioxetine 10-20 mg, Escitalopram 10-20 mg
- Where
- 16 sites in Finland, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
ALTO-300 in Depression
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
- Trial name
- NCT05118750
- Testing
- ALTO-300 oral (PO) tablet
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Alto Neuroscience
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
- Trial name
- NCT07592689
- Testing
- DT120
- Where
- 30 sites in United States
- Volunteers
- 165 people
- Sponsor
- Definium Therapeutics US, Inc.
Hiv, Loneliness
ADHOC Mindfulness-Based Research
The AMBR Study (ADHOC Mindfulness-Based Research Study) is a randomized controlled trial that examines the effectiveness of teaching mindfulness-based techniques through online lessons to combat loneliness, anxiety, and…
- Conditions
- Hiv, Loneliness, Depression, Anxiety
- Trial name
- AMBR (NCT04580082)
- Testing
- Mindfulness lessons
- Where
- United States
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Mazonson & Santas Inc.
Depressive Disorder and Anxiety Disorders
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
The study will consist of a screening period, 3 treatment periods and a post-treatment follow-up. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a…
- Trial name
- NCT00536679
- Testing
- GSK163090 capsule, fasted, GSK163090 Tablet, fasted, GSK163090 Tablet, fed
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depressive Disorder
Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects
The primary purpose of this study is to to assess the pharmacokinetics of paroxetine after single doses of paroxetine CR at the dose levels of 12.5, 25 and 50mg in healthy Japanese male volunteers.
- Trial name
- NCT00938184
- Testing
- Paroxetine 12.5 milligrams tablet, Paroxetine 25 milligrams tablet, Paroxetine 50 milligrams tablet
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects
To evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of GW117 ODT in healthy volunteers
- Trial name
- NCT06964711
- Testing
- GW117 ODT
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
Major Depressive Disorder
A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET
This study was a non-randomized, open-label clinical study to assess Serotonin transporter occupancy in the brain of healthy adults using 11C-DASB positron emission tomography (PET)
- Trial name
- NCT06476509
- Testing
- LV232 40mg, Escitalopram 20 mg, LV232 60mg
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Major Depressive Disorder
Phase 2b Study of ALTO-100 in MDD
The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
- Trial name
- NCT05712187
- Testing
- ALTO-100
- Where
- 34 sites in United States
- Volunteers
- 301 people
- Sponsor
- Alto Neuroscience
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.